Prior Authorization Required

Precertification of human fibrinogen concentrate (Fibryga, RiaSTAP) is required for all Aetna participating providers and members in applicable plan designs. Precertification/authorization must be obtained from Aetna’s Special Case Precert Unit at (855) 888-9046 prior to administration.

• Affected products: Fibryga, RiaSTAP
• Affected HCPCS: J7177/J7178 (where applicable)

Prior Authorization Requirements

Prior authorization requests must include the clinical indication (e.g., congenital fibrinogen deficiency or specific clinical scenario), planned dose, duration of therapy, and supporting clinical documentation demonstrating medical necessity.

• Planned dose and duration per FDA labeling or individualized dosing rationale
• Clinical documentation to justify off-label uses if requested

Prior Authorization — Non‑Congenital Indications

Use of human fibrinogen concentrate for non-congenital indications (e.g., acquired hypofibrinogenemia, trauma-associated hemorrhage, postpartum hemorrhage, peri-operative prophylaxis) may require prior authorization and is subject to evidence review; many of these indications are considered experimental/investigational or evidence-dependent and may be non-covered.

• Acquired hypofibrinogenemia — often experimental/INV
• Post-partum hemorrhage and trauma — limited or conflicting evidence; authorization not guaranteed

Experimental / Investigational Indications — Denial Risk

Aetna considers human fibrinogen concentrate experimental and investigational for listed indications where effectiveness is not established; requests for these indications may be denied.

• Examples: acquired hypofibrinogenemia, obstetric hemorrhage (PPH) in persons without congenital deficiency, trauma-associated hemorrhage in persons without congenital deficiency, intra-operative prophylactic use in neonatal/infant cardiac surgery

Evidence‑Dependent Authorization Risk

Authorization decisions for non‑FDA or evidence‑limited uses are evidence‑dependent. Lack of demonstrated clinical benefit, insufficient documentation, or use outside approved indications may result in denial.

• Requests lacking supporting clinical trial data or clear documentation of benefit may be denied
• Continuation requests must demonstrate ongoing benefit per initial criteria

PPH Outcomes and Timing Considerations

For postpartum hemorrhage (PPH), randomized and observational data have not consistently shown improved maternal outcomes with routine early administration of fibrinogen concentrate; timing of administration may affect outcomes and delayed use (>3 hours after transfusion start) has been associated with worse outcomes in some analyses.

• Early, systematic 3 g administration did not reduce transfusion needs or blood loss in a randomized trial (Ducloy‑Bouthors et al.)
• Observational data suggest administration >3 hours after RBC transfusion start associated with higher risk of near‑miss or death

Required Clinical Documentation

Clinical documentation submitted with prior authorization should include diagnosis, relevant lab values, prior therapies (e.g., plasma, cryoprecipitate), rationale for fibrinogen concentrate over alternatives, and notes on expected benefit.

• Diagnosis (congenital fibrinogen deficiency or clinical scenario)
• Prior and concurrent hemostatic therapies and responses
• Rationale for product selection (e.g., viral inactivation, rapid administration)

Required Clinical Documentation and Monitoring

Dosing, frequency, and monitoring must be individualized and supported by laboratory testing and clinical condition. Include documentation of target fibrinogen levels, monitoring plan, and response to treatment.

• Recommended targets (per Fibryga labeling): ~100 mg/dL for minor bleeding; ~150 mg/dL for major bleeding; retreat if below lower limits
• Documented plan for monitoring fibrinogen activity and clinical hemostasis

Testing and Timing Documentation

When used in acquired or peri‑operative settings, objective laboratory testing and timing must be documented (e.g., Clauss fibrinogen, ROTEM/TEG FIBTEM A5) and the interval between testing and product administration should be recorded to support individualized dosing decisions.

• Include fibrinogen activity (Clauss) and/or ROTEM/TEG FIBTEM A5 values with timestamps
• Document time from lab/point‑of‑care result to product administration

Step‑Therapy Considerations vs Cryoprecipitate

Step‑therapy considerations: clinicians should document why plasma or cryoprecipitate are not appropriate or sufficient if fibrinogen concentrate is requested in place of or prior to these alternatives; comparative trial data are limited and payers may require justification.

• If bypassing cryoprecipitate, provide clinical rationale (safety, supply, speed, viral inactivation)
• Comparative evidence is limited — authorization may require additional documentation

Consider Alternative Therapies

Consider alternative therapies (e.g., cryoprecipitate, plasma) where supported by evidence or local practice guidelines; documentation should explain why alternatives are not suitable when seeking coverage for fibrinogen concentrate.

• Cryoprecipitate is the standard intervention for acquired hypofibrinogenemia in many settings
• Provide justification when opting for fibrinogen concentrate (e.g., rapid availability, standardized dosing)

Prior Authorization Reference and Operational Notes

For operational questions and submission instructions, refer to Aetna’s Clinical Policy Bulletin process and contact the Special Case Precert Unit. Administrative or documentation deficiencies on the prior authorization submission may lead to delayed processing or denial.

• Contact: Aetna Special Case Precert Unit (855) 888‑9046
• See Clinical Policy Bulletin and policy history for submission details